(LOWER GWYNEDD, Pennsylvania, December 6, 2022) Tavotek Biotherapeutics, a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs, will attend the 2022 San Antonio Breast Cancer Symposium located in San Antonio, TX. 

Tavotek will showcase TAVO412, a novel multispecific antibody with unique 2:1:1 ratio of EGFR:cMet:VEGF binding arms with excellent activity against TNBC. 

About Tavotek

Tavotek Biotherapeutics is a multi-specific antibody drug company with the world's cutting-edge protein engineering technology, focusing on oncology and immunology diseases. The company's R&D is mainly built on three innovative breakthrough technology platforms, namely: TavoSelectTM, a bacteriophage biobank with AI assisted 3D selection; TavoPreciseTM, a sophisticated protein engineering platform that supports the development of bispecific and multi-specific antibodies, and TavoELITETM, an innovative synthetic biologic platform focusing on overcoming intracellular undruggable targets with particular focus on protein-protein interaction. With unique innovative R&D capabilities, biomarker-driven clinical development strategies, and efficient execution efficiency, Tavotek will provide treatment options with better efficacy, safety and convenience to advance medical care for patients.